Ortin Global Limited is an India-based company, which is engaged in the manufacturing and trading of pharmaceuticals, drugs and intermediates, to manufacture, sell or export all types of medicines, including ayurvedic, homeopathic, Unani, biochemical, nature cure and others. The Company is also engaged in the real estate business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-23	₹15.30	-0.13%	998
26-09-22	₹15.32	+0.13%	1,614
26-09-21	₹15.30	-4.26%	4,608
26-09-18	₹15.98	-3.97%	650
26-09-17	₹16.64	-3.26%	286

Delayed Quote Bombay S.E.

More quotes

Market Closed - Bombay S.E. 06:02:23 2026-09-23 EDT			5-day change	1st Jan Change
15.30 ^INR	-0.13%		-11.05%	+7.14%

09-07	Ortin Global Limited Announces Resignation of Prakruti Prashant Sawant as Whole-Time Director, Effective September 7, 2026	CI
08-14	Ortin Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Market Cap	124M 1.3M 1.14M 1.07M 980K 1.83M 1.84M 12.87M 4.99M 63.43M 4.88M 4.77M 206M	P/E 2025	-9.59x	P/E 2026	-15.5x
Enterprise Value	128M 1.34M 1.18M 1.11M 1.01M 1.89M 1.9M 13.28M 5.15M 65.46M 5.03M 4.92M 212M	EV / Sales 2025	23.3x	EV / Sales 2026	110x
Free-Float	78.15%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Bombay S.E.	ORTINGLOBE	Delayed
NSE India S.E.	ORTINGLOBE	Delayed

09-07	Ortin Global Limited Announces Resignation of Prakruti Prashant Sawant as Whole-Time Director, Effective September 7, 2026	CI
08-14	Ortin Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
06-17	Parveen Satija completed the acquisition of 0.003% stake in Ortin Global Limited for INR 3311.	CI
05-30	Ortin Global Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
02-14	Ortin Global Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
02-10	Parveen Satija proposed to acquire 26% stake in Ortin Global Limited for INR 31 million.	CI
11-14	Ortin Global to incorporate wholly owned subsidiary in Dubai	RE
11-14	Otin Global Limited Announces Incorporation	CI
11-14	Ortin Global Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
25-09-08	Ortin Global Limited Announces Resignation of Sashikant Shankarrao Igave as Non-Executive Non-Independent Director, Effective September 8, 2025	CI
25-08-25	Ortin Global Limited Approves Board Appointments	CI
25-08-14	Ortin Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
25-07-12	Ortin Global Limited Announces Set Up of New Corporate Office in Mumbai, Maharashtra	CI

Ortin Global Limited Stock

Stocks

ORTINGLOBE

INE749B01020

Pharmaceuticals

Valuation: Ortin Global Limited

Chart: Ortin Global Limited

Latest news: Ortin Global Limited

Press Releases: Ortin Global Limited

Quotes and Performance

Price Extremes

Managers and Directors: Ortin Global Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

25-10-03	ORTELIUS AB (formerly ORTELIUS International AB) – Half-Year Results for the First Half of 2025	AQ
25-10-02	ORTELIUS International AB officially listed under its own name	AQ

1 day	-0.13%
1 week	-11.05%
Current month	+0.72%
1 month	+3.31%
3 months	-8.93%
6 months	-1.29%
Current year	+7.14%

1 week	14.58	16.89
1 month	14.58	17.9
Current year	11.58	21.15
1 year	11.18	21.15
3 years	9.57	26.39
5 years	9.57	38.4
10 years	9.57	71.67

Manager	Title	Age	Since
Prashant Prakash Sawant CEO	Chief Executive Officer	-	2026-09-06
Wani Rahul Madanla DFI	Director of Finance/CFO	-	2025-07-10
Madhu Mala Solanki CMP	Compliance Officer	-	2025-03-31

Director	Title	Age	Since
Murali Krishna M. Sanka BRD	Director/Board Member	-	-
Parveen Satija BRD	Director/Board Member	-	2026-09-06
Mounika Reddy Pammi BRD	Director/Board Member	43	2025-05-25

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ORTIN GLOBAL LIMITED	-0.13%	-11.05%	+30.43%	-23.77%	1.3M
ELI LILLY AND COMPANY	-1.64%	+1.16%	+54.09%	+109.07%	1,043B
JOHNSON & JOHNSON	-0.01%	+0.71%	+52.44%	+67.71%	649B
ABBVIE INC.	-0.05%	+0.98%	+19.08%	+73.55%	469B
ROCHE HOLDING AG	-0.25%	+0.19%	+36.95%	+45.63%	355B
NOVARTIS AG	+0.98%	+2.91%	+20.59%	+27.91%	270B
ASTRAZENECA PLC	-1.91%	+2.42%	+10.41%	+12.53%	262B
AMGEN INC.	-1.01%	+7.90%	+41.59%	+51.70%	222B
GILEAD SCIENCES, INC.	-0.85%	+2.50%	+32.32%	+101.80%	189B
NOVO NORDISK A/S	-2.53%	-7.47%	-32.63%	-60.67%	175B
Average	-0.22%	+0.03%	+26.53%	+40.54%	363.3B
Weighted average by Cap.	+0.44%	+1.34%	+35.89%	+65.85%

	2025	2026
Net sales	3.42M 35.75K 31.38K 29.5K 26.97K 50.4K 50.77K 354K 137K 1.75M 134K 131K 5.66M	1.08M 11.32K 9.93K 9.34K 8.54K 15.95K 16.07K 112K 43.47K 553K 42.5K 41.56K 1.79M
Net income	-8.46M -88.36K -77.55K -72.9K -66.65K -125K -125K -876K -339K -4.32M -332K -325K -13.99M	-7.4M -77.29K -67.84K -63.77K -58.3K -109K -110K -766K -297K -3.77M -290K -284K -12.24M
Net Debt	-1.24M -12.91K -11.33K -10.65K -9.74K -18.2K -18.34K -128K -49.61K -631K -48.49K -47.43K -2.04M	3.99M 41.66K 36.57K 34.37K 31.43K 58.73K 59.16K 413K 160K 2.03M 156K 153K 6.6M